초록 ▼

Described are human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding mo

Described are human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.

대표청구항 ▼

1. An isolated human monoclonal antibody having opsonic phagocytic killing activity against at least two different Staphylococcus species and against at least three different strains of Staphylococcus aureus, wherein the antibody is selected from the group consisting of: i) an antibody with a heavy

1. An isolated human monoclonal antibody having opsonic phagocytic killing activity against at least two different Staphylococcus species and against at least three different strains of Staphylococcus aureus, wherein the antibody is selected from the group consisting of: i) an antibody with a heavy chain comprising the variable region of SEQ ID NO:30 and a light chain comprising the variable region of SEQ ID NO:36;ii) an antibody with a heavy chain comprising the variable region of SEQ ID NO:117 and a light chain comprising the variable region of SEQ ID NO:177;iii) an antibody with a heavy chain comprising the variable region of SEQ ID NO:119 and a light chain comprising the variable region of SEQ ID NO:179;iv) an antibody with a heavy chain comprising the variable region of SEQ ID NO:121 and a light chain comprising the variable region of SEQ ID NO:181; andv) an antibody with a heavy chain comprising the variable region of SEQ ID NO:155 and a light chain comprising the variable region of SEQ ID NO:215. 2. The human monoclonal antibody of claim 1, characterized in having opsonic phagocytic killing activity when the Staphylococcus species are in logarithmic growth phase and in static phase. 3. The human monoclonal antibody of claim 1, wherein the Staphylococcus species comprise S. aureus and S. epidermidis. 4. The human monoclonal antibody of claim 2, wherein the Staphylococcus species comprise S. aureus and S. epidermidis. 5. An immunoconjugate comprising: the human monoclonal antibody of claim 1 and at least one tag. 6. An immunoconjugate comprising: the human monoclonal antibody of claim 2 and at least one tag. 7. An immunoconjugate comprising: the human monoclonal antibody of claim 3 and at least one tag. 8. An immunoconjugate comprising: the human monoclonal antibody of claim 4 and at least one tag. 9. A composition comprising the human monoclonal antibody of claim 1, and at least one pharmaceutically acceptable excipient. 10. A composition comprising the human monoclonal antibody of claim 2, and at least one pharmaceutically acceptable excipient. 11. A composition comprising the human monoclonal antibody of claim 3, and at least one pharmaceutically acceptable excipient. 12. A composition comprising the human monoclonal antibody of claim 4, and at least one pharmaceutically acceptable excipient. 13. The composition of claim 9, further comprising at least one other therapeutic agent. 14. The composition of claim 10, further comprising at least one other therapeutic agent. 15. A method of diagnosing, prophylaxing, and/or treating a staphylococcal disease in a subject, wherein the method comprises utilizing the human monoclonal antibody of claim 1 for the diagnosis, prophylaxis, treatment, or combination thereof, of the staphylococcal disease.